| Revenue | 67,379.08a | 67,155.26a |
| Cost of sales | -62,168.3a | -61,882.13a |
| Gross profit | 5,210.79a | 5,273.14a |
| Other items of income | — | — |
| Net gain/(loss) arising from changes in fair value of biological assets | 25.39a | -2.8a |
| Finance income | 395.68a | 503.16a |
| Other operating income | 400.59a | 570.31a |
| Other items of expense | — | — |
| Selling and distribution expenses | -1,953.44a | -2,107.05a |
| Administrative expenses | -1,160.38a | -1,149.93a |
| Other operating expenses | -175.19a | -160.96a |
| Finance costs | -1,202.99a | -1,251.53a |
| Non-operating items | -15.23a | -37.87a |
| Share of results of joint ventures | 40.75a | 105.74a |
| Share of results of associates | 179.14a | 214.06a |
| Profit before tax | 1,745.11a | 1,956.25a |
| Income tax expense | -516.64a | -298.08a |
| Profit after tax | 1,228.47a | 1,658.17a |
| Attributable to | — | — |
| Owners of the Company | 1,169.81a | 1,524.83a |
| Non-controlling interests | 58.65a | 133.35a |